Company intelligence / Profile preview

Silk Road Entertainment

Sunnyvale, California, United States

Ownership: Private
Development stage: Other

Overview

TCAR is a commercially available minimally invasive procedure that has demonstrated reduced risk of stroke, death, myocardial infarction, and cranial nerve injury compared to traditional methods; over 85,000 procedures performed by end of 2023, with projections to exceed 100,000 by mid-2024[2][4][6].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Genesis MedTech (exclusive distribution in China)

Beyond the preview

Go deeper on Silk Road Entertainment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silk Road Entertainment.

Explore the full profile